1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
-
  1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  1. Launch

Nanjing Haina Medical Technology Co.,Ltd.

Have updates for this profile?  Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Year established

2001

Location

Nanjing Jiangsu China

Primary Industry

Pharmaceuticals

About

Established in 2001 and based in Nanjing, China, Nanjing Haina Medical Technology Co.,Ltd. operates as a pharmaceutical developer that provides new drug development process services. The company's R & D area has exceeds 5000 square meters and the investment exceeds CNY 400 million. The core research team of the company has more than 200 employees and more than 50% has master's degree. And the R&D team divides into synthesis department, preparation department and analysis department. Nanjing Healthnice Pharmaceutical Technology Co.,Ltd., Nanjing Oceanwide Pharmaceutical Technology Co., Ltd. and Nanjing Yinuo Pharmaceutical Technology Co., Ltd. are the subsidiary of the company. Boda medicine has become the strategic partner of the company in July 2021. The business of the company includes new drug discovery, pharmaceutical and clinical research, biological sample detection. The company's products and services include contract development and manufacturing organization (CDMO) services, consistency evaluation, technology transfer, technical service and clinical services. Consistency evaluation includes oral solid preparation and injection consistency evaluation. Technology transfer includes transfer of clinical approval documents for guanfaxin hydrochloride raw materials and tablets, transfer of clinical approval documents for fluconazole raw materials and liniments, transfer of clinical approval documents for pirepanide raw materials and tablets. The company's R&D platforms include drug synthesis platform, drug preparation platform impurity analysis, impurity analysis platform and pharmacokinetic research platform. Impurity analysis platform includes study on genotoxic impurities, synthesis, separation and preparation of impurities.
Current Investors
Jiangsu Jincai Investment

Request a demo to show more

Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Website
www.healthnice.net
Verticals
HealthTech
Company Stage
Series B
Total Amount Raised
Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.